Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

BTK inhibitors (BTKi) are an important treatment for CLL. As BTKi are given until intolerance or disease progression, resistance is a major challenge. Progressive disease (PD) during BTKi treatment is associated with mutations BTK itself, or the immediate downstream protein, PLCG2. These can be dete...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.1899-1899
Hauptverfasser:	Rogers, Kerry A, McLaughlin, Eric, Wei, Lai, Bhat, Seema A, Crouse, Arianna, Grever, Michael R., Jones, Dan, Kittai, Adam S, Lozanski, Gerard, Moran, Mollie, Reid, Mark, Sass, Ellen J, Suresh, Swetha, Byrd, John C., Woyach, Jennifer A.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!